Comparative Study of Triglyceride Level in Ischemic Heart Disease Patients in different age groups of Patients in south east Rajasthan
Journal Title: International Journal of Drug Regulatory Affairs - Year 2018, Vol 6, Issue 2
Abstract
Backgrounds: Elevated body triglycerides have been implicated as a risk factor of ischemic heart disease (IHD). Objectives: To study the association of serum triglyceride with ischemic heart disease and to assess the relationship of serum triglyceride with other established conventional risk factors. Methods: A cross sectional case-control study of 75 cases of IHD and 75 controls without having any evidence of IHD/CHD between age group 30-70 years. Serum triglyceride levels were estimated by using Colorimetric Method and other risk factors by enzymatic methods. Results: Mean serum triglyceride (263.674 ± 89.029mg/dl) was significantly higher in cases than controls (98.833 ± 62.682mg/dl). Amongst the patients of IHD, significantly higher level of Serum triglyceride was found in diabetics (340.63±90.78mg/dl) than nondiabetics (225.19±58.30mg/dl), male elderly (>60years of age) smokers (304.20±88.60mg/dl) compared to non smoker (206.37±48.88mg/dl), elderly male with high (>150mg/dl) LDL (323.48±86.73mg/dl) compared to patients with normal (<150mg/dl) LDL (249.33±66.12 mg/dl). Similarly male patients of IHD with high (>40mg/dl) VLDL had significantly higher serum triglyceride (326.49±77.95mg/dl) compared to male patients with normal (<40mg/dl) VLDL (257.18±85.46mg/dl). Conclusion: High serum triglyceride level (>200mg/dl) may provide a cost effective tool for predicting an impending ischemic heart disease especially in diabetic patients, male elderly smokers, elderly males with high LDL, male patients of ischemic heart disease with high VLDL level.
Authors and Affiliations
Darab Singh Underwal, Sushma Pandey, Deepak Gupta
QUALITY STANDARDS FOR MEDICAL DEVICES
Formerly with more augmented disabilities, Medical devices have become decisive device in many circumstances. As these are more perilous, the manufacturer should endow with an ideal medical device in aspects of safety &...
“ME-TOO” DRUG REVOLUTION: A PRODUCT OF REGULATORY IMPROPRIETY
Amidst all the brouhaha, often the regulatory agencies, for instance the United States Food and Drug Administration’s (US-FDA) role in bringing about what is being so cleverly termed as the ‘me-too drug revolution’, has...
ACTD: BRIDGE BETWEEN REGULATORY REQUIREMENTS OF DEVELOPED AND DEVELOPING COUNTRIES
Regulatory Dossier contains data which when submitted to the regulatory authority, provides for the review and ultimate approval of a drug product. Once approved, an applicant may manufacture and market the drug to provi...
A comprehensive study of Regulatory compliance for Biosimilars in US, EU and India
The biopharmaceutical industry has gained significant interest in the last decade as the numbers of blockbuster biologic products are losing their patent rights. The regulatory authority is also providing marketing appro...
COMMON DEFICIENCIES RAISED BY VARIOUS REGULATORY AGENCIES
Timely Product registration is a challenge in today’s scenario. Regulatory agencies are keen in assessing CTD sections like redefining starting material of Drug substance manufacturing, Pharmaceutical development, impuri...